Clinical Trials Browser

NCT05704933 2026-04-06

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

Phase EARLY_PHASE1 Completed

1 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT07492680 2026-03-25

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Phase 2 Not yet recruiting

260 enrolled

CNSDermatologicGastrointestinal

Brain Neoplasms, Melanoma, Pancreatic Neoplasms

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Phase 1/2 Recruiting

134 enrolled

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT03340129 2026-02-02

ABC-X

Phase 2 Recruiting

218 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT02910700 2025-12-17

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

Phase 2 Active not recruiting

52 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT02374242 2025-12-10

ABC

Phase 2 Active not recruiting

76 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma, Neoplasm Metastasis

NCT04674683 2025-09-24

Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

Phase 3 Active not recruiting

450 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04511013 2025-09-11

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Phase 2 Recruiting

112 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT06712927 2025-09-08

Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

Phase 2 Recruiting

60 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT05341349 2025-07-30

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

Phase 1 Active not recruiting

1 enrolled

CNSDermatologic

Uveal Melanoma, Brain Neoplasms, Melanoma

NCT02978404 2024-06-28

Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases

Phase 2 Completed

26 enrolled

CNSDermatologicGenitourinaryThoracic

Clear-cell metastatic renal cell carcinoma, Brain Neoplasms, Melanoma, Small Cell Lung Carcinoma

NCT02621515 2024-05-06

CA209-322

Phase 2 Terminated

7 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT03563729 2023-07-13

MEMBRAINS

Phase 2 Recruiting

80 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04434560 2022-07-26

Neoadjuvant Immunotherapy in Brain Metastases

Phase 2 Terminated

1 enrolled 7 charts

BreastCNSDermatologicGenitourinaryGynecologicThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02716948 2021-11-30

SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine

Phase 1 Completed

17 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT03728465 2021-02-03

Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma

Phase 2 Terminated

6 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma